• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    A 'Toxic Byproduct of an Imperfect Higher Education System' — Famous Short Seller Known as 'The Assassin' Strikes Her Newest Target

    2/8/24 8:59:14 AM ET
    $ATGE
    $BHC
    Other Consumer Services
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATGE alert in real time by email


    Fahmi Quadir, featured in the Netflix series "Dirty Money" for her success in predicting and betting on the collapse of Valeant Pharmaceuticals International Inc. (now known as Bausch Health Cos. Inc. (NYSE: BHC), is taking on Adtalem Global Education Inc. (NYSE:ATGE) in a scathing short report targeting the for-profit education company.

    Adtalem, which was previously known by its more well-known name DeVry University, was the first education provider to ever launch an initial public offering (IPO), which occurred in 1991. 

    Since then, it has seen its share price soar about 5,000% in the often divisive for-profit education space. 

    Don't Miss:

    • Did you know StartEngine Private is your portal to investing in venture-backed businesses without spending millions?
    • Join the ranks of investors like Bill Gates and Mark Cuban by tapping into early-stage startups. Get the inside scoop on this innovative startup here.

    If Quadir, whose nickname is The Assassin, is correct, given her successful track record of shorting companies, Adtalem's good fortunes could come crashing down.

    On the day of her report's release, Adtalem's shares dropped as much as 23% before paring back some losses. 

    According to Quadir, Adtalem "is completely uninvestable." She said everyone "should be angry that our money is being abused in such a careless, careless kind of way," which she supports by citing that 70% of their revenue comes from federal tax dollars.

    It's not the first time Adtalem has faced controversy. 

    Trending: Cheddar was acquired for $200 million yielding a return of 370.37% for its investors. This startup aims to replicate and potentially surpass this success.

    As recently as February 2022, the Biden administration had $415 million of student debt waived for close to 16,000 student loan borrowers, many of these being DeVry graduates. These borrowers had a unique clause used to justify this decision — their debt forgiveness came from a rule in the law known as borrower defense, which ensures borrowers who were defrauded can get loan relief.

    This was the first time the Department of Education granted the borrower defense claim. All the while, Adtalem was allowed to maintain business as usual, while also being permitted to continue accessing federal student loans. 

    Adtalem fought back against the short seller's report, moving up its scheduled earnings call by two days to promptly address the allegations to reassure its investors.

    Adtalem President and CEO Stephen Beard shot down the report's claims, saying, "Lots of the claims in the report are unsubstantiated" and highlighted the company's "fantastic student outcomes" and a "constructive relationship with our creditors and regulators."

    It's worth remembering that activist short sellers stand to benefit from the company's share price falling when they go public with their claims, and it is unknown when Quadir will be willing to cover her short. 

    Whether Adalem can put this newest controversy behind it remains to be seen.

    Read Next:

    • This startup is accepting investors for as little as 25 cents – what’s the catch?
    • Here is where your most successful angel investment may be hidden.
    Get the next $ATGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATGE
    $BHC

    CompanyDatePrice TargetRatingAnalyst
    Bausch Health Companies Inc.
    $BHC
    12/9/2025$8.00Equal Weight
    Barclays
    Adtalem Global Education Inc.
    $ATGE
    4/23/2025$135.00Buy
    Jefferies
    Bausch Health Companies Inc.
    $BHC
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    Bausch Health Companies Inc.
    $BHC
    7/10/2024$8.00Mkt Perform
    Raymond James
    Adtalem Global Education Inc.
    $ATGE
    10/27/2023$47.00 → $55.00Neutral → Outperform
    Robert W. Baird
    Bausch Health Companies Inc.
    $BHC
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    Adtalem Global Education Inc.
    $ATGE
    7/7/2023$44.00Market Perform → Outperform
    BMO Capital Markets
    Bausch Health Companies Inc.
    $BHC
    6/16/2023Outperform → Market Perform
    TD Cowen
    More analyst ratings

    $ATGE
    $BHC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Bausch Health Companies Inc.

    DEFA14A - Bausch Health Companies Inc. (0000885590) (Filer)

    4/8/26 4:06:22 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Bausch Health Companies Inc.

    DEF 14A - Bausch Health Companies Inc. (0000885590) (Filer)

    4/8/26 4:05:43 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Companies Inc. filed SEC Form 8-K: Leadership Update

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    3/2/26 5:17:03 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATGE
    $BHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering

    The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channelsLAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced Biafine® Skin Recovery Emulsion is now offered through convenient online ordering in the United States. The well-known French skincare formula is available through select online channels.First developed in France in 1971, Biafine® is a lightweight emulsion formula designed to support the skin's natural barrier function while helping to maintain skin hydration and comfort. For decades, the formula has been recognized by dermatol

    4/14/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program

    Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the 2026 ASPIRE HIGHER Scholarship Program, with applications open through June 10, 2026. The program will award six exceptional students, impacted by dermatologic conditions with scholarships of up to $10,000 each to support their pursuit of higher education. "It is an honor to continue the AS

    3/26/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATGE
    $BHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Phelan Kenneth J bought $49,931 worth of shares (508 units at $98.29), increasing direct ownership by 3% to 18,783 units (SEC Form 4)

    4 - Adtalem Global Education Inc. (0000730464) (Issuer)

    11/5/25 4:12:06 PM ET
    $ATGE
    Other Consumer Services
    Real Estate

    Lead Independent Director Malafronte Michael W bought $91,850 worth of shares (1,000 units at $91.85), increasing direct ownership by 1% to 100,445 units (SEC Form 4)

    4 - Adtalem Global Education Inc. (0000730464) (Issuer)

    11/4/25 4:43:27 PM ET
    $ATGE
    Other Consumer Services
    Real Estate

    $ATGE
    $BHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Adtalem Global Education with a new price target

    Jefferies initiated coverage of Adtalem Global Education with a rating of Buy and set a new price target of $135.00

    4/23/25 8:14:48 AM ET
    $ATGE
    Other Consumer Services
    Real Estate

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATGE
    $BHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Leung Sandra

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:30:13 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Paulson John

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:20:34 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wechsler Amy B

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    4/2/26 6:19:05 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATGE
    $BHC
    Financials

    Live finance-specific insights

    View All

    Bausch Health to Announce First Quarter 2026 Results on April 29, 2026

    LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:                                            Wednesday, April 29, 2026Time:                                            5:00 p.m. U.S. EDTWebcast:                                      http://ir.bauschhealth.com/events-and-

    3/31/26 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y

    2/18/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adtalem Global Education Second Quarter Fiscal Year 2026 Results; Raises Fiscal Year 2026 Adjusted Earnings Per Share Guidance

    Total enrollment up 6.3% YoY Revenue up 12.4% YoY Diluted earnings per share $2.11; Adjusted EPS $2.43, growth of 34.3% YoY Second quarter highlights Total student enrollment 97,010, up 6.3% year-over-year, achieved tenth straight quarter of growth Revenue $503.4 million, up 12.4% year-over-year Walden University achieved tenth straight quarter of total enrollment growth, up 13.0% year-over-year, highest total enrollment in university history Chamberlain University achieved fourteenth straight quarter of pre-licensure BSN total enrollment growth Sustaining momentum, GAAP net income $76.4 million; adjusted EBITDA $154.9 million, up 23.9% year-over-year Capital allocat

    1/28/26 4:15:00 PM ET
    $ATGE
    Other Consumer Services
    Real Estate

    $ATGE
    $BHC
    Leadership Updates

    Live Leadership Updates

    View All

    Ross University School of Medicine Welcomes New Dean

    Dr. Cheryl Holmes will lead the institution from its Barbados campus Covista (NYSE:ATGE), America's largest healthcare educator, today announced Cheryl Holmes, M.D., a fellow of the Royal College of Physicians of Canada with a master's degree in health professions education, as the next dean of Ross University School of Medicine (RUSM) effective March 16. "I am thrilled to welcome Dr. Holmes, and confident that her impressive experience spanning clinical practice, research and academic leadership will be invaluable to our students, faculty and staff," said Scott Liles, president of medical and veterinary for Covista. "Covista has a key role to play in addressing the healthcare workforce

    2/17/26 9:00:00 AM ET
    $ATGE
    Other Consumer Services
    Real Estate

    Adtalem Names Megan Noel its New Chief Corporate Affairs Officer

    Noel brings two decades of corporate affairs leadership and strategic stakeholder engagement experience Adtalem Global Education (NYSE:ATGE), the leading healthcare educator in the United States, has appointed Megan Noel as its Chief Corporate Affairs Officer, effective immediately. Noel will lead Adtalem's corporate affairs function, overseeing communications, investor relations, government relations, impact and alumni engagement, ensuring the company's stakeholder engagement strategy supports its growth strategy. She will be responsible for driving strategic outcomes across Adtalem's portfolio of institutions while engaging a broad range of stakeholders, including its nearly 10,000 empl

    5/12/25 8:00:00 AM ET
    $ATGE
    Other Consumer Services
    Real Estate

    Chamberlain University Appoints Mary Beth Kingston to its Board of Trustees

    Mary Beth Kingston joins Chamberlain University's Board of Trustees, bringing her visionary leadership and innovative approach to nursing to the nation's largest nursing school. Chamberlain University, an Adtalem Global Education (NYSE:ATGE) institution and largest nursing school in the country1, has appointed Mary Beth Kingston, PhD, RN, FAAN, to its board of trustees as chair, effective immediately. A 2024 recipient of the prestigious Lifetime Achievement Award from the American Organization for Nursing Leadership (AONL), Kingston brings more than 40 years of experience in the healthcare industry to Chamberlain University. A visionary leader in nursing, Mary Beth Kingston brings her inn

    3/19/25 8:00:00 AM ET
    $ATGE
    Other Consumer Services
    Real Estate

    $ATGE
    $BHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adtalem Global Education Inc.

    SC 13G/A - Adtalem Global Education Inc. (0000730464) (Subject)

    11/12/24 1:28:11 PM ET
    $ATGE
    Other Consumer Services
    Real Estate

    SEC Form SC 13G filed by Adtalem Global Education Inc.

    SC 13G - Adtalem Global Education Inc. (0000730464) (Subject)

    11/4/24 10:58:07 AM ET
    $ATGE
    Other Consumer Services
    Real Estate

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care